MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson's program
Synaffix and MacroGenics have signed a deal to codevelop and commercialize a clinical platform for antibody-drug conjugates to fight cancer.
Synaffix will license out its GlycoConnect antibody conjugation platform, polar spacer technology and toxSYN linker payloads. In return, it will get $586 million in upfront and milestone payments across the three programs and is eligible for royalties on commercial sales.
MacroGenics will be responsible for R&D, manufacturing and commercialization of the ADCs, and Synaffix will support MacroGenics research and manufacturing components for GlycoConnect, HydraSpace and toxSYN. Each of these programs are designed to effectively enable ADCs, and they will be combined with MacroGenics proprietary antibody and bispecific DART antibody platform to create next-generation ADCs.
“The collaboration with MacroGenics is an important milestone for Synaffix as our ADC technology will be deployed for the generation of both monospecific and bispecific ADCs,” Synaffix CEO Peter Van de Sande said in a press release. “We are pleased to further expand the use of our technology with another leading biotech company that has deep product development capabilities and a long-term commitment to delivering novel therapies for the treatment of cancer.”
Nonprofit donates $3.4M to battle Parkinson’s
A Parkinson’s disease nonprofit and Domainex are teaming up to develop small molecule therapies that could potentially slow the progression of the disease by targeting neuroinflammation.
Parkinson’s UK will invest up to $3.42 million in the project through its drug development arm, dubbed the Parkinson’s Virtual Biotech. Domainex will carry out drug discovery, in the hopes of sending a candidate to clinical trials.
Patients with Parkinson’s experience chronic inflammation in the brain, which is believed to play a role in damaging brain cells and causing the condition. The organization has identified small molecules that target a protein on the surface of the microglia, a main immune cell in the brain that can become overactive in Parkinson’s.
“We look forward to working with the team at Parkinson’s UK and supporting the wider Parkinson’s community to progress the development of potentially life-changing medicines,” Domainex CEO Tom Mander said in a statement. “Having studied microglial cells during my DPhil and spent a good part of my early industrial career working on macrophage activation, I am especially interested to see whether a new therapy emerges from our partnership.”